Hey golfyeti... after reading that article seeing that it would take years to develop a treatment it does seem to suggest that Resverlogix and apabetalone (rvx-208) are years ahead.

Also, if I read it right the author stated that it is much easier to develop drugs to control the protein production rather than to splice the gene. Well this is what epigenetics does and what apabetalone already does and achieves a 55% relative risk reduction of MACE events and a 77% MACE reduction in patients with diabetes mellitus, CVD and low HDL. As we all know apabetalone is already 6 months into it's phase 3 BETonMACE trial.

Yes, the share price is extremely low and I wish I new the barriers? Certainly it is the business side and poor communications along with a lack of credible representation in the USA because it is not on NASDAQ.

Very frustrating to say the least.

Toinv